December 2002
Volume 43, Issue 13
ARVO Annual Meeting Abstract  |   December 2002
ERG Revisited in Patients on Hydroxychloroquine Treatment
Author Affiliations & Notes
  • RT Tzekov
    Department of Ophthalmology Stanford University Stanford CA
  • A Serrato
    Department of Ophthalmology Stanford University Stanford CA
  • MF Marmor
    Department of Ophthalmology Stanford University Stanford CA
  • Footnotes
    Commercial Relationships   R.T. Tzekov, None; A. Serrato, None; M.F. Marmor, None.
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 1203. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      RT Tzekov, A Serrato, MF Marmor; ERG Revisited in Patients on Hydroxychloroquine Treatment . Invest. Ophthalmol. Vis. Sci. 2002;43(13):1203.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: Our aim was to evaluate findings of full-field electroretinography (ERG) and multifocal electroretinography (mfERG) in patients taking hydroxychloroquine (HCQ) for different periods of time. We reviewed records for 26 patients using HCQ for 1.5-30 yrs all of whom had an ERG and/or mfERG. Methods: Both ERG and mfERG were done according to the international standards and guidelines. Oscillatory potentials (OPs) were recorded under scotopic and photopic conditions. They were digitally filtered (60-300Hz) and their amplitudes, implicit times and power spectrum were measured. MfERG to 103 hexagons was recorded and the parameters of the first order kernel were measured and analyzed. Results: Out of 26 patients tested only 4 had signs of macular toxicity attributable to the HCQ treatment. However, scotopic OPs showed almost universal decrease in amplitudes. Out of 22 patients who had full-field ERGs, 20% showed lack of scotopic OP4 and 2/3 of those without maculopathy had at least one abnormal full-field ERG parameter. Out of 16 patients who had mfERG, 10 showed either decreased amplitudes or prolonged implicit times, including 3 patients with maculopathy. Conclusion: Retinal function was altered in many patients taking HCQ even without clinical signs of maculopathy. The reason for this remains unknown. This might represent either sub-clinical vasculopathy from the systemic disease process or some retinotoxic effect of HCQ.

Keywords: 395 electroretinography: clinical • 393 electrophysiology: clinical • 460 macula/fovea 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.